Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovita Biological Technology Co's revenue for the
three
months ended in Mar. 2026 was ¥108.8 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ¥323.9 Mil.
Innovita Biological Technology Co's Revenue per Share for the
three
months ended in Mar. 2026 was ¥0.80.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥2.37.
Warning Sign:
Innovita Biological Technology Co Ltd revenue per share has been in decline for the last 5 years.
During the past 8 years, Innovita Biological Technology Co's highest 3-Year average Revenue per Share Growth Rate was 39.50% per year. The lowest was -30.50% per year. And the median was 3.40% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Innovita Biological Technology Co Revenue Related Terms
Innovita Biological Technology Co Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688253 vs VRTX, REGN, RVMD: Revenue Comparison
For the Biotechnology subindustry, Innovita Biological Technology Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovita Biological Technology Co Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovita Biological Technology Co's Revenue distribution charts can be found below:
* The bar in red indicates where Innovita Biological Technology Co's Revenue falls into.
Innovita Biological Technology Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥323.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovita Biological Technology Co (SHSE:688253) has a Revenue of ¥323.9 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Innovita Biological Technology Co and its competitors.
Is Innovita Biological Technology Co's Revenue too high?
Innovita Biological Technology Co's current Revenue is ¥323.9 Mil. Overall, Innovita Biological Technology Co has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innovita Biological Technology Co's Revenue compare to VRTX and REGN?
Innovita Biological Technology Co's Revenue of ¥323.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Innovita Biological Technology Co and its competitors. Innovita Biological Technology Co's current Revenue is ¥323.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovita Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Innovita Biological Technology Co (SHSE:688253) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥20.90, compared to a current price of ¥52.77 — trading 152.5% above its estimated fair value. The current Revenue is ¥323.9 Mil. Innovita Biological Technology Co's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Innovita Biological Technology Co (SHSE:688253), the current Revenue is ¥323.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovita Biological Technology Co (SHSE:688253) Overvalued in 2026?
Based on GuruFocus' analysis, Innovita Biological Technology Co stock appears to be overvalued.
The current stock price of ¥52.77 is trading 152.5% above its estimated GF Value™ of ¥20.90.
GuruFocus considers Innovita Biological Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688253:
Revenue: ¥323.9 Mil
GF Value™: ¥20.90 vs. price of ¥52.77 (152.5% above fair value)
No single metric tells the full story. See the SHSE:688253 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovita Biological Technology Co Ltd is a biotechnology company focusing on the research and development, production, and sales of POCT in vitro diagnostic products.
60GF Score
Get the complete analysis for SHSE:688253
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688253 has been successfully added to your 
